TG101209, an orally bioavailable JAK2 inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. TG101209 potently inhibits JAK2 (IC(50)=6 nM), FLT3 (IC(50)=25 nM) and RET (IC(50)=17 nM) kinases, with significantly less activity against other tyrosine kinases including JAK3 (IC(50)=169 nM). TG101209 also inhibited STAT3 activation and survivin expression, and sensitized HCC2429 (DER=1.34, p=0.002) and H460 (DER=1.09, p=0.006) cells to radiation in clonogenic assays. In vivo, addition of TG101209 to radiation in lung xenografts produced a significant tumor growth delay (>10 days). TG101209 has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
Cell Experiment | |
---|---|
Cell lines | Ba/F3 cells, MPLW515L, CTLL-2 cells and HEL and K562 cells |
Preparation method | XTT assay for cell proliferation. In brief, approximately 2*103 cells were plated into microtiterplate wells in 100 ml RPMI-1640 growth media with indicated concentrations of inhibitor. The relative growth of cells was quantified at 24-h intervals using Cell Proliferation Kit II (XTT) as per manufacturer’s guidelines (Roche, Indianapolis, IN, USA). After incubation, 20 ml of XTT was added to the wells and allowed to incubate for 4–6 h. The colored formazan product was measured spectrophotometrically at 450 nm with correction at 650 nm, and IC50 values were determined using the GraphPad Prism 4.0 software. Data were subjected to a non-linear regression-fit analysis and IC50 values were determined as the concentration, that inhibited proliferation by 50%. All experiments were done in triplicate and the results normalized to growth of untreated cells. |
Concentrations | 0~100 μ M |
Incubation time | 24 h |
Animal Experiment | |
---|---|
Animal models | JAK2V617F-induced hematopoietic disease in a nude mouse model |
Formulation | DMSO |
Dosages | 10, 30 and 100mg/kg bid |
Administration | oral gavage |
Molecular Weight | 509.67 |
Formula | C26H35N7O2S |
CAS Number | 936091-14-4 |
Solubility (25°C) | DMSO 72 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related JAK Products |
---|
A-005
A-005 is a potentially first-in-class, brain-penetrating TYK2 allosteric inhibitor for studies related to neuroinflammatory and neurodegenerative diseases. |
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2. |
JAK2/FLT3-IN-1 TFA
JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. |
ZT55
ZT55 is an orally active and highly-selective JAK2 inhibitor with an IC50 value of 0.031 μM. |
ZM39923
ZM39923 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.